Richard D Brokx
Overview
Explore the profile of Richard D Brokx including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matulonis U, Lee J, Lasonde B, Tew W, Yehwalashet A, Matei D, et al.
Eur J Cancer
. 2012 Aug;
49(1):121-31.
PMID: 22921155
Purpose: The purpose was to assess the activity and side effect profile of ENMD-2076, an oral anti-angiogenic and anti-proliferative kinase inhibitor, in platinum-resistant recurrent epithelial ovarian cancer (EOC), fallopian tube...
2.
Fletcher G, Brokx R, Denny T, Hembrough T, Plum S, Fogler W, et al.
Mol Cancer Ther
. 2010 Dec;
10(1):126-37.
PMID: 21177375
ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival: angiogenesis, proliferation, and the cell cycle....
3.
Anandan S, Ward J, Brokx R, Denny T, Bray M, Patel D, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(21):5995-9.
PMID: 17827005
We have designed and synthesized a series of structurally novel hydroxamic acid-based histone deacetylase (HDAC) inhibitors characterized by a zinc chelating head group attached directly to a thiazole ring. The...
4.
Poon G, Brokx R, Sung M, Gariepy J
J Mol Biol
. 2006 Nov;
365(4):1217-31.
PMID: 17113101
Tetramerization of the human p53 tumor suppressor protein is required for its biological functions. However, cellular levels of p53 indicate that it exists predominantly in a monomeric state. Since the...
5.
Anandan S, Ward J, Brokx R, Bray M, Patel D, Xiao X
Bioorg Med Chem Lett
. 2005 Apr;
15(8):1969-72.
PMID: 15808449
Inhibitors of histone deacetylases (HDAC) are emerging as a promising class of anti-cancer agents. A mercaptoamide functionality was designed as a bidentate zinc chelator and incorporated into the hydroxamic acid...
6.
Brokx R, Scheek R, Weljie A, Vogel H
J Struct Biol
. 2004 Apr;
146(3):272-80.
PMID: 15099569
The backbone dynamic properties of uniformly (15)N-labeled calcium-saturated calmodulin (Ca(2+)-CaM) in 35% 2,2,2-trifluoroethanol (TFE) have been examined by (15)N NMR relaxation methods. This particular solvent was chosen in order to...
7.
Brokx R, Revers L, Zhang Q, Yang S, Mal T, Ikura M, et al.
Biochemistry
. 2003 Nov;
42(47):13817-25.
PMID: 14636048
The human glycoprotein MUC1 mucin plays a critical role in cancer progression. Breast, ovarian, and colon cancer cells often display unique cell-surface antigens corresponding to aberrantly glycosylated forms of the...
8.
Brokx R, Bolewska-Pedyczak E, Gariepy J
J Biol Chem
. 2002 Nov;
278(4):2327-32.
PMID: 12433927
The human p53 tetramerization domain (called p53tet; residues 325-355) spontaneously forms a dimer of dimers in solution. Hydrophobic interactions play a major role in stabilizing the p53 tetramer. However, the...
9.
10.
Vogel H, Brokx R, Ouyang H
Methods Mol Biol
. 2002 Feb;
172:3-20.
PMID: 11833356
No abstract available.